Press Room MediaRoom Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients - Kevzara is now available to U.S. patients - Mon, 22 May 2017 17:47:00 -0400 Allegra® Allergy Gears Up for Bike to Work Day Across the U.S. -- New Initiative Encourages Americans to Help Reduce Air Pollution & Enjoy the Outdoors this Spring Allergy Season -- Thu, 11 May 2017 08:30:00 -0400 Sanofi Pricing Principles for the U.S. Op-Ed by Olivier Brandicourt Tue, 09 May 2017 07:00:00 -0400 Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment - New U.S. survey reveals significant unmet needs when it comes to treatments and support for those living with RA - Tue, 02 May 2017 08:30:00 -0400 Sanofi and Regeneron Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by US FDA - New action date for Kevzara U.S. BLA is May 22, 2017 - Fri, 28 Apr 2017 08:28:00 -0400